# US 8,278,293 B2 · Diazo bicyclic Smac mimetics and the uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,293 B2
- Document ID: US8278293B2
- Status: Granted
- Kind: B2
- Application number: 12/159,249
- Filed: 2008-04-14
- Published: 2010-10-28
- Granted: 2012-10-02
- Earliest claimed: 2007-04-13
- Assignees: The Regents of the University of Michigan
- Inventors: Shaomeng Wang; Yuefeng Peng; Haiying Sun; Qian Cai; Zaneta Nikolovska-Coleska; Jianfeng Lu; Su Qiu
- Web page: https://patentgrep.com/patent/US8278293B2

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 487/04: Ortho-condensed systems
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

## Claims

### Claim 1

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 2

A compound selected from the group consisting of:
or the free base thereof or another pharmaceutically acceptable salt thereof.

### Claim 3

A compound of formula:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

A pharmaceutical composition comprising the compound of claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 5

A process for preparing a compound of Formula XI
wherein
A1 and A2 are independently selected from the group consisting of hydrogen and optionally substituted alkyl;
V is selected from the group consisting of N;
W is selected from the group consisting of CH;
X is selected from the group consisting of hydrogen and optionally substituted C1-3 alkyl;
Y is NHCO where NH is connected to the ring and CO is connected to W;
T is C═O;
U is NR1R2;
Z is (CR1R2)r, wherein r is 0;
m is 1;
each of R1 and R2 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and
R7 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;
comprising condensing a compound of Formula XII
wherein A1, A2, V, W, X, Y, T, U and m have the meanings described above for Formula XI;
with R7CO-L, and
L is a leaving group, to form a compound of Formula XI.
